BIOLASE reported Q3 2023 financial results with a total revenue of $10.9 million. The company experienced a decrease in overall revenue compared to the previous year, but saw a 10% year-over-year increase in total consumable sales. Gross margin improved significantly to 34%, and the operating loss was reduced by 52% year over year.

BIOLASE reported a 17% year-over-year increase in total revenue, reaching $14.3 million, the highest quarterly revenue since Q4 2015. Consumable sales also hit a record $4.1 million, up 36% year-over-year. The company is implementing cost-saving initiatives expected to result in $5 to $6 million in annualized savings beginning in Q3.

BIOLASE, Inc. announced its financial results for the third quarter ended September 30, 2022, with total revenue of $12.0 million, up 26% year over year. U.S. laser sales increased 35% year over year and U.S. consumable sales increased 22% year over year. The company is increasing its 2022 full year revenue guidance and now expects full year net revenue to increase at least 20% from 2021 levels.

BIOLASE, Inc. announced financial results for the second quarter ended June 30, 2022, with total revenue of $12.2 million, up 34% year over year. U.S. laser sales increased 70% year over year and U.S. consumable sales increased 42% year over year.

BIOLASE reported a strong fourth quarter with a 46% increase in total revenue year-over-year, reaching $12.4 million. The company's gross margin improved to 40%, and it maintained a solid cash position of $30.0 million. They also anticipate first quarter net revenue to exceed $9.0 million.

BIOLASE reported a 46% increase in net revenue to $9.5 million for the third quarter of 2021, driven by strong demand for dental lasers. Gross margin improved to 51%, and the company maintained a strong cash position of $33.4 million.

BIOLASE reported a strong second quarter with a 211% increase in net revenue to $9.1 million compared to the same period last year. The company's performance was driven by increased demand for dental lasers, with over 70% of U.S. laser sales coming from new customers. The company also provided revenue guidance for the third quarter of 2021, expecting significant year-over-year improvement.

BIOLASE reported a strong sequential revenue growth in Q3 2020. Total revenue more than doubled sequentially, while U.S. laser revenue increased 16% year over year. The company significantly strengthened its balance sheet with an $18.0 million equity raise.

Biolase reported a significant decrease in revenue for Q2 2020, primarily due to the impact of the COVID-19 pandemic. However, the company emphasized its products' alignment with new safety standards in dental practices and highlighted recent financing activities that bolstered its balance sheet.